Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IACS-6274 |
Synonyms | |
Therapy Description |
IACS-6274 (IPN60090) inhibits glutaminase-1 (GLS1), which prevents the conversion of glutamine to glutamate, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IACS-6274 | IACS6274|IACS 6274|IPN60090|IPN-60090|IPN 60090 | Glutaminase Inhibitor 3 | IACS-6274 (IPN60090) inhibits glutaminase-1 (GLS1), which prevents the conversion of glutamine to glutamate, potentially resulting in decreased tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03894540 | Phase I | IACS-6274 IACS-6274 + Pembrolizumab IACS-6274 + Paclitaxel | A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours | Terminated | USA | 0 |
NCT05039801 | Phase I | Bevacizumab + IACS-6274 + Paclitaxel IACS-6274 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | Recruiting | USA | 0 |